✦ LIBER ✦

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

✍ Scribed by Gani, Ray; Giovannoni, Gavin; Bates, David; Kemball, Belinda; Hughes, Steve; Kerrigan, John

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PRS28 COST-UTILITY ANALYSES OF DISEASE-M

✍ M Yang; WW Tseng; SS Sansgiry 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Cost-Effectiveness Analyses of Natalizum

✍ Nishikawa, A.M.; Paladini, L.; Liamas, A.L.; Bueno, C.C.; Clark, O.A.C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB